ClinicalTrials.gg
CompletedNCT00471380Updated Mar 16, 2010Results posted

A Phase IV Study of Travoprost + Brinzolamide to Treat Glaucoma or Ocular Hypertension

A Phase 4 interventional study of travoprost 0.004% and brinzolamide 1% and fixed combination of timolol 0.5% and dorzolamide 2% plus travoprost vehicle in Glaucoma and Ocular Hypertension, sponsored by Alcon Research. Completed at 1 site in Italy. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2010-03-16.

Sponsored by Alcon Research (part of Alcon) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies testing travoprost in Glaucoma — none open to participants now, none under way, none of them phase 3. Travoprost · Glaucoma.

Enrollment
30th of 39
46 · median 89
Started
2007
with 3 others
Phase 4
25 of 42
none open now
Registered
13th of 42
by date
Lead sponsor
27 of 42
Alcon Research

Among the 42 studies testing travoprost in Glaucoma, this one is the 30th largest by enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2007, is one of 25 in phase 4, and was the 13th registered.

Glaucoma

1,419 studies on the registry are indexed under Glaucoma; 220 are open to participants now.

Browse Glaucoma studies →

Open to participants now

None of the 42 studies testing travoprost in Glaucoma is open now. The open studies under Glaucoma, anywhere →

About travoprost

Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 42 studies testing travoprost in Glaucoma as a file.
02

Study summary

Double blind, crossover randomized, multicentric study to compare efficacy and tolerability of concomitant administration of travoprost and brinzolamide versus timolol-dorzolamide fixed combination in patients with glaucoma or ocular hypertension

03

Conditions studied

  • Glaucoma
  • Ocular Hypertension
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written
  • Diagnosis of bilateral Primary open angle glaucoma or ocular hypertension
  • Intra Ocular Pressure above 19 millimeters mercury at screening visit at 8:00 AM
  • Stable visual field in last 6 months
  • 6 weeks wash out from previous topical medications

Exclusion criteria

Exclusion Criteria:

  • Age
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double
Enrollment
46 participants (actual)

Study arms

  • Active comparator
    Crossover group ABB

    3 period, 2 treatment cross-over model: Participants received Treatment A, which was concomitant administration of travoprost 0.004% (ophthalmic drops, 1 drop/eye at approximately 19:45 p.m.) and brinzolamide 1% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.) for period 1 for 8 weeks. Then participants received Treatment B, which was fixed combination of timolol 0.5% and dorzolamide 2% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.), and travoprost vehicle (ophthalmic drops, 1 drop/eye, at approximately 19:45 p.m.) for Period 2 (8 weeks) and Period 3 (8 weeks)

    Drug: travoprost 0.004% and brinzolamide 1% · Drug: fixed combination of timolol 0.5% and dorzolamide 2% plus travoprost vehicle

  • Active comparator
    Crossover group BAA

    3 period, 2 treatment cross-over model: Participants received Treatment B, which was fixed combination of timolol 0.5% and dorzolamide 2% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.), and travoprost vehicle (ophthalmic drops, 1 drop/eye, at approximately 19:45 p.m.) for Period 1 (8 weeks). Then participants received Treatment A, which was concomitant administration of travoprost 0.004% (ophthalmic drops, 1 drop/eye at approximately 19:45 p.m.) and brinzolamide 1% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.) for Period 2 (8 weeks) and Period 3 (8 weeks).

    Drug: travoprost 0.004% and brinzolamide 1% · Drug: fixed combination of timolol 0.5% and dorzolamide 2% plus travoprost vehicle

Interventions

  • Drugtravoprost 0.004% and brinzolamide 1%

    Drug page: Travoprost

    Group A = concomitant administration of travoprost 0.004% (ophthalmic drops, 1 drop/eye at approximately 19:45 p.m.) and brinzolamide 1% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.)

  • Drugfixed combination of timolol 0.5% and dorzolamide 2% plus travoprost vehicle

    group B = fixed combination of timolol 0.5% and dorzolamide 2% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.), and travoprost vehicle (ophthalmic drops, 1 drop/eye, at approximately 19:45 p.m.).

06

What researchers measure

Primary outcomes

  1. Intra Ocular Pressure (IOP)

    Intra Ocular Pressure, calculated as AUC (area under the curve) of IOP measured from 8.00 a.m. to 8.00 p.m, at different time-points

    Time frame: Baseline, end of each period (week 8, week 16, week 24)

07

Results

Posted Mar 11, 2010

Participant flow

46 patients suffering from POAG or ocular hypertension, with an intraocular pressure that was insufficiently controlled were recruited.

First Intervention
Participant flow — First Intervention
MilestoneCrossover Group ABBCrossover Group BAA
Started2224
Completed1820
Not completed44
Second Intervention
Participant flow — Second Intervention
MilestoneCrossover Group ABBCrossover Group BAA
Started1820
Completed1816
Not completed04
Third Intervention
Participant flow — Third Intervention
MilestoneCrossover Group ABBCrossover Group BAA
Started1816
Completed1714
Not completed12

Outcome measures

PrimaryIntra Ocular Pressure (IOP)

Intra Ocular Pressure, calculated as AUC (area under the curve) of IOP measured from 8.00 a.m. to 8.00 p.m, at different time-points

Time frame:
Baseline, end of each period (week 8, week 16, week 24)
Reported as:
Mean · mm Hg (millimeters mercury)*week
Intra Ocular Pressure (IOP)
mm Hg (millimeters mercury)*weekCrossover Group ABBCrossover Group BAA
Week 8179.20 ± 25.42191.89 ± 52.59
Week 16188.82 ± 32.05196.26 ± 59.07
Week 24201.50 ± 41.01191.93 ± 41.39

Adverse events

Collected over 6 Months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A—0/22 (0%)11/22 (50%)
Treatment B—2/24 (8.3%)3/24 (12.5%)
Most frequent serious events
Most frequent serious events
EventTreatment ATreatment B
Sternal FractureInjury, poisoning and procedural complications0/221/24
Traumatic Brain InjuryInjury, poisoning and procedural complications0/221/24
Most frequent other events
Most frequent other events
EventTreatment ATreatment B
Eye IrritationEye disorders8/222/24
Conjunctivitis AllergicEye disorders3/221/24

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Overall Study Population
<=18 years0
Between 18 and 65 years23
>=65 years23
Sex: Female, Male
Sex: Female, Male(Participants)Overall Study Population
Female28
Male18
08

Study locations

1 site
  • Catania
    Catania, 95123, Italy
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2007 and a primary completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2010, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2007
First posted
May 9, 2007
Start
Mar 2007
Primary completionActual
Oct 2008
Results first posted
Mar 11, 2010
Last update
Mar 16, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00471380
Lead sponsor
Alcon Research
First posted
May 9, 2007
Start date
Mar 2007
Primary completion
Oct 2008
Results posted
Mar 11, 2010
Last update
Mar 16, 2010

Study contacts

Marcello Fornoni
study director · Alcon Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Travoprost

Start the discussion